id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-306076-ygfnkgqp	Fujita, Yu	RNAi Therapeutic Platforms for Lung Diseases	2013-02-06		.txt	text/plain	8419	495	43	Although the success in delivering siRNAs intranasally in rodents cannot be completely extrapolated to human use because of the significant differences in lung anatomy [37] , this approach has potential for the clinical application of siRNAs. Phase II clinical trials have been initiated for the treatment of respiratory syncytial virus (RSV) infection, making use of intranasal application of naked chemically modified siRNA molecules that target viral gene products [17, 38] (see Section 3.1.1. The simultaneously inhibition of several genes would also minimize the risk of drug resistance normally encountered with small molecule-based therapies, involving siRNAs and miRNAs. There have already been significant improvements in siRNAs for primary or metastatic lung cancer treatment by targeting oncogenes such as Akt1 [9] , Wilms tumor 1 (WT1) [12] , overexpressed genes such as the insulin-like growth factor receptor 1 (IGF-1R) [77] , NUPR1 [53] and EZH2 [78] .	./cache/cord-306076-ygfnkgqp.txt	./txt/cord-306076-ygfnkgqp.txt